Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Adolescents, ages 13-18

• Meets criteria for alcohol and/or substance use disorder and attention deficit hyperactivity disorder.

Exclusion Criteria:

• Adolescents who are pregnant.

• Have a history of seizure disorder, other neurological or medical disorder for which medication treatment may present a considerable risk.

• History of pervasive development disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders.

• Currently on other psychotropic medications from which discontinuation would present a significant risk.

• A current episode of major depressive disorder or a diagnosis of bipolar disorder.

• Diagnosis of dependence for any substance other than marijuana.

• Adolescents with a full-scale IQ below 80.